PMID: 2498537Jun 16, 1989Paper

The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy

JAMA : the Journal of the American Medical Association
G F PierceC M Kessler

Abstract

Treatment of hemophilia, although greatly improved in recent years, continues to be problematic owing to infectious complications of blood product replacement therapy. This report examines the therapeutic options presently available for the treatment of hemophilia, focusing on the potential for repeated viral exposure to influence the progression of infectious disease, decreased risks of viral transmission with blood products produced using newer viral inactivation procedures, higher economic costs of newer blood products, and the current inadequate supply of blood products in the United States.

Citations

Aug 12, 1999·Haemophilia : the Official Journal of the World Federation of Hemophilia·H A LiebmanC K Kasper
Jun 16, 2001·Haemophilia : the Official Journal of the World Federation of Hemophilia·A YoshiokaUNKNOWN Coganate FS Study Group
Oct 1, 1995·Haemophilia : the Official Journal of the World Federation of Hemophilia·E P BolivarD B Brettler
Jan 6, 1994·The New England Journal of Medicine·L W Hoyer
Jun 2, 1994·The New England Journal of Medicine·G F Pierce
Apr 20, 2012·Haemophilia : the Official Journal of the World Federation of Hemophilia·J M Lusher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

© 2022 Meta ULC. All rights reserved